Table 3 Probability of one treatment being better

From: International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours – EURO EWING 2012 Protocol

Observed 3-year EFS			Observed HR			P (HR <1.00)	P (HR <0.81)	P (HR >1.21)
VIDE	Difference	VDC/IE	Number of events	HR	ln (HR)	P (HR <1.00)	P (HR <0.81)	P (HR >1.21)
0.70	0.00	0.70	180	1.00	0.00	0.50	0.07	0.10
0.70	0.05	0.75	165	0.81	−0.21	0.92	0.50	0.00
0.70	−0.05	0.65	195	1.21	0.19	0.09	0.00	0.50
0.70	0.025	0.725	173	0.90	−0.10	0.75	0.23	0.03
0.70	− 0.025	0.675	188	1.10	0.10	0.25	0.02	0.27

EFS event-free survival, HR hazard ratio, VDC/IE vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide, VIDE vincristine, ifosfamide, doxorubicin and etoposide

Back to article page

ISSN: 1745-6215

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com